Title : Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.

Pub. Date : 2002 Oct

PMID : 12435290






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 It was shown that the addition of sequential docetaxel (100 mg/m2) to CVAP neoadjuvant chemotherapy resulted in a significantly enhanced clinical response rate (94% vs. 64%) and a substantially increased complete histopathological response rate (34% vs. 16%) when compared to patients receiving CVAP alone. Docetaxel amyloid beta precursor protein Homo sapiens